First quarter with 2% growth in Swiss francs, 7%[1] at constant exchange rates

NEXT STORY
Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
PREV STORY
Medtronic Provides Update on COVID-19 Pandemic Response and Impact
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

PDS Biotechnology Signs Cooperative Research and Development Agreement with National Cancer Institute to Perform a Phase 2 Clinical Study of PDS0101 in Combination with Other Immune-modulating Agents in Advanced HPV-related Cancers

author_avatar
NASDAQ Market News

Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives

author_avatar
NASDAQ Market News

Guardant Health Reports Second Quarter 2020 Financial Results

author_avatar
NASDAQ Market News